HF2624 (Legislative Session 94 (2025-2026))
Provisions in the prescription monitoring program changed.
Related bill: SF2806
AI Generated Summary
Purpose of the Bill
The bill aims to update and amend the provisions related to the Minnesota Prescription Monitoring Program (PMP), which is designed to monitor and regulate the prescribing and dispensing of controlled substances. The revisions target enhancing data accuracy, strengthening oversight, and increasing accessibility for authorized users.
Main Provisions
Definitions Updates: New definitions are clarified for terms like "controlled reportable substances," which now include substances like butalbital and gabapentin, and FDA-approved opioid antagonists.
Electronic Reporting System: The Minnesota State Board of Pharmacy is tasked with maintaining an electronic prescription monitoring system, allowing for contracted technical assistance to manage the system.
Data Reporting Requirements: Dispensers are required to report detailed data for each prescription, such as prescriber and patient details, drug details, and dispensing dates. Dispensers must notify patients about these reporting requirements.
Use of Data: The data from the PMP will be used to identify suspicious prescription patterns and unauthorized prescriptions. Careful measures are included to ensure the data is encrypted and only accessible to authorized users for specified terms.
Access Procedures: Defines permissible users who can access PMP data, including healthcare providers and pharmacists, under specific conditions and for legitimate medical purposes. Establishes procedures for prescribers to regularly check on patients receiving ongoing opioid prescriptions.
Auditing and Security: Implements regular audits of access to ensure compliance with permissible use, while establishing strict security measures for data access. Requires permissible users to audit their agents' use of data.
Patient Rights: Allows patients to request access to their PMP data and see who has accessed their prescription history.
Significant Changes to Existing Law
Enhanced Controlled Substance Monitoring: Expands the list of substances monitored and specifies the inclusion of specific FDA-approved substances.
Increased Oversight: Introduces stronger auditing processes and detailed reporting requirements to ensure correct data usage.
Privacy and Access: Updates privacy controls, maintaining patient confidentiality while allowing necessary access to prescribers and pharmacists.
Mandatory Prescriber Registration: All prescribers authorized to prescribe controlled substances must register with the PMP, ensuring widespread adoption of monitoring practices.
Relevant Terms
controlled substances, prescription monitoring, butalbital, gabapentin, opioid antagonists, Minnesota State Board of Pharmacy, electronic reporting system, permissible users, data encryption, auditing, patient access, privacy controls, prescriber registration.
Bill text versions
- Introduction PDF file
Actions
| Date | Chamber | Where | Type | Name | Committee Name |
|---|---|---|---|---|---|
| March 19, 2025 | House | Floor | Action | Introduction and first reading, referred to | Health Finance and Policy |
Citations
[
{
"analysis": {
"added": [
"Includes substances not previously categorized, such as butalbital and FDA-approved opioid antagonists."
],
"removed": [],
"summary": "The bill clarifies definitions related to controlled substances, referencing the existing statute section 152.02 for controlled Reportable substances.",
"modified": [
"Expands the definition of controlled reportable substances."
]
},
"citation": "152.02"
},
{
"analysis": {
"added": [],
"removed": [],
"summary": "The bill includes a reference to the definition of 'dispense or dispensing' as provided in section 151.01.",
"modified": [
"Clarifies what activities are included in dispensing and excludes the direct administering of a substance to a patient by a licensed health care professional."
]
},
"citation": "151.01"
},
{
"analysis": {
"added": [],
"removed": [],
"summary": "The bill refers to dispensing prescriptions under section 156.18, indicating an exception for veterinarians.",
"modified": [
"Specifies that a veterinarian dispensing prescriptions is not classified as a dispenser under this bill."
]
},
"citation": "156.18"
},
{
"analysis": {
"added": [],
"removed": [],
"summary": "The bill mentions personnel or designees of health-related licensing boards listed under section 214.01.",
"modified": [
"Identifies permissible users with access to the prescription monitoring program data for investigative purposes."
]
},
"citation": "214.01"
},
{
"analysis": {
"added": [],
"removed": [],
"summary": "The bill relates to the legitimate prescribing of controlled substances for pain under section 152.125.",
"modified": [
"Ensures prescribers are not subject to disciplinary action for prescribing controlled substances according to this section."
]
},
"citation": "152.125"
},
{
"analysis": {
"added": [],
"removed": [],
"summary": "The bill uses definitions from section 13.02, including private data on individuals.",
"modified": [
"Establishes data privacy standards for the prescription monitoring database."
]
},
"citation": "13.02"
},
{
"analysis": {
"added": [],
"removed": [],
"summary": "The bill references the health professionals services program established under section 214.31.",
"modified": [
"Allows access to prescription monitoring program information for individuals monitored by the program with their consent."
]
},
"citation": "214.31"
},
{
"analysis": {
"added": [],
"removed": [],
"summary": "The bill allows for sharing data with health-related licensing boards under section 214.33.",
"modified": [
"Permits data sharing strictly as allowed under specified conditions."
]
},
"citation": "214.33"
},
{
"analysis": {
"added": [],
"removed": [],
"summary": "The bill refers to prescribing protocols established under the opioid prescribing improvement program in section 256B.0638.",
"modified": [
"Specifies protocols following surgery and the related opioid prescribing guidelines."
]
},
"citation": "256B.0638"
},
{
"analysis": {
"added": [],
"removed": [],
"summary": "The bill references health care directives under chapter 145C for accessing data.",
"modified": [
"Defines who can consent to data access on behalf of patients receiving controlled substances."
]
},
"citation": "145C"
}
]